Skip to main content

Day: February 25, 2021

Capitala Group Announces Investment in Fremont-Wright, LLC

CHARLOTTE, N.C., Feb. 25, 2021 (GLOBE NEWSWIRE) — Capitala Group (“Capitala”), a provider of capital to lower middle market companies, announced today that it closed on an investment in Fremont-Wright, LLC (“Fremont-Wright”). Capitala partnered with SouthWorth Capital Management, LLC (“SouthWorth Capital”) on the transaction in support of Fremont-Wright’s next phase of growth.Based in Memphis, TN, Fremont-Wright is a holding company comprised of nine entities that provide engineering, surveying, and architectural services. The company leverages local expertise combined with national reach to deliver service across eleven states.“We are enthusiastic about working with SouthWorth Capital again and look forward to participating in Fremont-Wright’s growth as they continue to look for suitable acquisitions in their target markets,” stated...

Continue reading

Coherus Management to Present at Upcoming Investor Conferences

REDWOOD CITY, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced today that senior management will present at the following investor conferences in March.41st Annual Cowen Healthcare Conference on Monday, March 1 at 4 p.m. ETBarclays Global Healthcare Conference on Tuesday, March 9 at 1:15 p.m. ETThe audio portion of the presentation will be available on the investors’ page of the Coherus BioSciences website at http://investors.coherus.com.About Coherus BioSciencesCoherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system.For additional information, please visit www.coherus.com.ContactMcDavid StilwellEVP, Financial...

Continue reading

Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores

Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvementTo date 34 patients, or approximately one-third of the total, have been enrolled at 22 sites, including 20 patients in the treatment arm and 14 patients in the control armLAWRENCEVILLE, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on its Phase I/II OVATION 2 Study with GEN-1 in patients with advanced ovarian cancer, including interim observations. GEN-1 is Celsion’s DNA-mediated interleukin-12 (IL-12) immunotherapy designed using TheraPlas, its proprietary, synthetic, non-viral nanoparticle delivery system platform.The...

Continue reading

Årsrapport for Værdipapirfonden Sydinvest

(Selskabsmeddelelse 07/2021)Bestyrelsen i Syd Fund Management A/S har i dag den 25. februar 2021 behandlet og godkendt årsrapporten for 2020.Download/bestil rapportenÅrsrapport 2020 for Værdipapirfonden Sydinvest er vedlagt og kan downloades på sydinvest.dk eller bestilles via tlf. 74 37 33 00. Venlig hilsenSyd Fund Management A/STlf. 74 37 33 00Vedhæftet filVS årsrapport 2020 -Bestyrelsesgodkendt

Continue reading

TAAT Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) Brings ‘Same Format, Different Ingredients’ Model to Smoking Market

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) announces the availability of a broadcast titled, “Beyond Tobacco: TAAT Innovation Delivers New Smoking Alternative.”To hear the AudioPressRelease, please visit: The NetworkNewsAudio News PodcastTo view the full editorial, please visit: https://www.nnw.fm/e5KjQHealth and wellness has become a top priority in today’s world, creating a global climate of consumers clamoring for choices that offer the same experiences they’ve come to enjoy but with different ingredients. This is on full display with the surging popularity of alternative food and beverages that create the same feeling that one is accustomed with only a change in ingredients. Today, burgers and seafood look, smell and taste like hamburger and...

Continue reading

Concrete Pumping Holdings Sets First Quarter Fiscal Year 2021 Earnings Conference Call for Thursday, March 11, 2021

DENVER, Feb. 25, 2021 (GLOBE NEWSWIRE) — Concrete Pumping Holdings, Inc. (Nasdaq: BBCP) (“CPH” or the “Company”), a leading provider of concrete pumping and waste management services in the U.S. and U.K., will hold a conference call on Thursday, March 11, 2021, at 5:00 p.m. Eastern time to discuss its financial results for the first quarter of fiscal year 2021 ended January 31, 2021. The Company will report its financial results in a press release prior to the conference call.CPH’s CEO Bruce Young and CFO Iain Humphries will host the conference call, followed by a question and answer period.Date: Thursday, March 11, 2021Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)Toll-free dial-in number: 1-877-407-9039International dial-in number: 1-201-689-8470Conference ID: 13716974Please call the conference telephone number 5-10 minutes...

Continue reading

Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research

‒ EB612 When Added to Standard of Care Led to a Statistically Significant Decrease in Supplemental Calcium Usage –‒ Oral Human Parathyroid Hormone (1-34) Has the Potential to Have a Major Impact on Compliance, Adherence, Therapeutic Impact and Quality of Life for Patients –BOSTON and JERUSALEM, Feb. 25, 2021 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today the publication of the results of its previously completed Phase 2a study of EB612 in the Journal of Bone and Mineral Research. The article, titled “Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study,” discussed the results of the four-month study in which EB612 was evaluated in 2015 as an adjunct to standard calcium and vitamin D...

Continue reading

Abercrombie & Fitch Co. Commits to Renewable Energy in Its Global Home Office and Distribution Centers

NEW ALBANY, Ohio, Feb. 25, 2021 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF), a leading, global specialty retailer of apparel and accessories, today announced its commitment to source all electricity used at its New Albany, OH Global Home Office and Distribution Centers from renewable generation beginning in 2023.The retailer, which owns Abercrombie & Fitch, abercrombie kids, Hollister, and Gilly Hicks, has signed a 13-year, 100% renewable energy supply agreement for Abercrombie & Fitch Co.’s corporate headquarters and two New Albany Distribution Centers with fellow Ohio-based company AEP Energy, a subsidiary of American Electric Power. The agreement is for approximately 30,000 megawatt hours annually and will reduce approximately 16,000 metric tons of carbon from the atmosphere each year. This is equivalent...

Continue reading

ChemoCentryx to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:Raymond James 42nd Annual Institutional Investors ConferenceWednesday, March 3 at 2:10 p.m. Eastern TimeH.C. Wainwright Global Life Sciences ConferenceOn-demand presentation available beginning Monday, March 9 at 7:00 a.m. Eastern TimeWebcasts of the presentations can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. A replay of each presentation will be available on the Company’s website for two weeks following the respective presentation dates.About ChemoCentryxChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and...

Continue reading

Assure Holdings to Acquire Sentry Neuromonitoring

DENVER, Feb. 25, 2021 (GLOBE NEWSWIRE) — Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that effective February 24, 2021, it has signed a Term Sheet (“Term Sheet”) to acquire (the “Acquisition”) Sentry Neuromonitoring, LLC (“Sentry”), one of the largest IONM service providers in Texas, for a purchase price of $3,500,000. The purchase price to be paid is $1,225,000 in cash and $2,275,000 in Assure common stock, subject to escrow, TSX Venture Exchange and other requirements. Under the Term Sheet, Assure will acquire Sentry’s contracts, employees, business relationships and assets including accounts receivable, and assume up to $250,000 of its debt. The proposed Acquisition will take the form of either an asset or equity...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.